Form D · Biotechnology
Meditope Biosciences, Inc.
Pasadena, CA · CIK 0001567712
Offering snapshot reported Oct 8, 2015 · SEC filing
- Reported sold
- $1.62M Offering amount: $5M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 24, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 8, 2015 | Initial | $1,624,080 | No comparison | 23 | SEC filing |
| Feb 27, 2013 | Initial | $2,105,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-248981
Source: Form D, filed Oct 8, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Heng Wei Chang | Director |
| Michael Goldberg | Director |
| Stephanie Hsieh | Director, Executive |
| Rob Kramer | Director |
| Robert Mc Kenzie | Director |
| George Prendergast | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
301 N. Lake Avenue Suite 900
Pasadena, CA, 91101
Pasadena, CA, 91101